Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project.

Isabelle Cleynen, Juan R González, Carolina Figueroa, Andre Franke, Dermot McGovern, Martin Bortlík, Bart J A Crusius, Maurizio Vecchi, Marta Artieda, Magdalena Szczypiorska, Johannes Bethge, David Arteta, Edgar Ayala, Silvio Danese, Ruud A van Hogezand, Julian Panés, Salvador Amado Peña, Milan Lukas, Derek P Jewell, Stefan Schreiber, Severine Vermeire, Miquel Sans
Year of publication:
Journal title abbreviated:
Journal title long:
Gut : journal of the British Society of Gastroenterology
Impact factor:
Through genome-wide association scans and meta-analyses thereof, over 70 genetic loci (Crohn''s disease (CD) single nucleotide polymorphisms (SNPs)) are significantly associated with CD. We aimed to investigate the influence of CD-SNPs and basic patient characteristics on CD clinical course, and develop statistical models to predict CD clinical course.This retrospective study included 1528 patients with CD with more than 10 years of follow-up from eight European referral hospitals. CD outcomes of interest were ileal (L1), colonic (L2) and ileocolonic disease location (L3); stenosing (B2) or penetrating behaviour (B3); perianal disease; extraintestinal manifestations; and bowel resection. A complicated disease course was defined as stenosing or penetrating behaviour, perianal disease and/or bowel resection. Association between CD-SNPs or patient characteristics and specified outcomes was studied.Several CD-SNPs and clinical characteristics were statistically associated with outcomes of interest. The NOD2 gene was the most important genetic factor, being an independent predictive factor for ileal location (p=2.02×10(-06), OR=1.90), stenosing (p=3.16×10(-06), OR=1.82) and penetrating (p=1.26×10(-02), OR=1.25) CD behaviours, and need for surgery (p=2.28×e-05, OR=1.73), and as such was also the strongest factor associated with a complicated disease course (p=6.86×10(-06), OR=2.96). Immunomodulator (azathioprine/6-mercaptopurine and methotrexate) use within 3 years after diagnosis led to a reduction in bowel stenoses (p=1.48×10(-06), OR=0.35) and surgical rate (p=1.71×10(-07), OR=0.34). Association between each outcome and genetic scores, created using significant SNPs in the univariate analysis, revealed large differences in the probability of developing fistulising disease (IL23R, LOC441108, PRDM1, NOD2; p=9.64e-4, HR=1.43), need for surgery (IRGM, TNFSF15, C13ORF31, NOD2; p=7.12×10(-03), HR=1.35), and stenosing disease (NOD2, JAK2, ATG16L1; p=3.01×10(-02), HR=1.29) among patients with low and high score.This large multicentre cohort study has found several genetic and clinical factors influencing the clinical course of CD. NOD2 and early immunomodulator use are the clinically most meaningful predictors for its clinical course.